Stay updated on APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial

Sign up to get notified when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the dose of APG-115 in combination with pembrolizumab for patients with metastatic melanomas or advanced solid tumors. This change reflects a modification in the treatment plan for the clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:44:09.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    37%
    Check dated 2024-05-22T21:34:28.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:18:15.000Z thumbnail image

Stay in the know with updates to APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.